Analysts Offer Insights on Healthcare Companies: Bio-Techne (TECH) and Mineralys Therapeutics, Inc. (MLYS)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bio-Techne (TECH) and Mineralys Therapeutics, Inc. (MLYS) with bullish sentiments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bio-Techne (TECH)
William Blair analyst Matt Larew maintained a Buy rating on Bio-Techne today. The company’s shares closed last Wednesday at $47.41.
According to TipRanks.com, Larew is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Techne with a $57.67 average price target, implying a 1.7% upside from current levels. In a report issued on April 24, TipRanks – PerPlexity also upgraded the stock to Buy with a $66.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Mineralys Therapeutics, Inc. (MLYS)
In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Mineralys Therapeutics, Inc., with a price target of $54.00. The company’s shares closed last Wednesday at $30.12.
According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mineralys Therapeutics, Inc. with a $51.14 average price target, implying a 73.9% upside from current levels. In a report issued on April 27, TD Cowen also initiated coverage with a Buy rating on the stock.
Read More on TECH:
